Advertisement
BIIB or INCY or PFE
Which Stock Would AI Choose? Biogen (BIIB) vs. Incyte (INCY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- BIIB has shown strong momentum with 10.8% gains over recent three months, outperforming the healthcare sector, driven by robust Q4 earnings and pipeline progress in neurology.
- INCY reported 28% Q4 revenue growth to $1.51 billion from Jakafi and Opzelura, though EPS missed estimates, with shares up 39% over the past year amid oncology expansions.
- PFE trades at a low valuation with YTD gains around 9%, supported by oncology advancements and a high dividend yield, but faces post-COVID revenue pressures.
- All three biotech giants exhibit relative strength in their niches—neurology for BIIB, hematology/oncology for INCY, and diversified pharma for PFE—with BIIB leading recent performance.
- Market sentiment favors growth in specialized therapies, but valuation sensitivity varies, with PFE appearing undervalued on forward metrics.
Introduction
This stock comparison evaluates BIIB (Biogen), INCY (Incyte), and PFE (Pfizer) in the current market environment, focusing on their relative performance, sector positioning, and growth drivers. These biotechnology and pharmaceutical leaders operate in overlapping therapeutic areas like neurology, oncology, and immunology, making them relevant for investors seeking exposure to innovative drug development amid shifting healthcare trends. Traders monitoring momentum and stability, as well as long-term investors assessing pipeline catalysts and valuation, will find insights into how these stocks stack up in terms of recent price behavior, sentiment, and market positioning.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) is a leading biotechnology firm specializing in therapies for neurological diseases, including multiple sclerosis, spinal muscular atrophy, and Alzheimer's. Recent market activity has seen BIIB shares gain approximately 10.8% over the past three months, outperforming the healthcare sector ETF (XLV), with year-to-date returns around 5-9% and a one-year increase of over 30%. This momentum stems from stronger-than-expected Q4 earnings, where revenue of $2.3 billion beat estimates despite a yearly decline, fueled by newer products like Leqembi, Skyclarys, Zurzuvae, and Qalsody generating over $1 billion annually. Positive sentiment is further bolstered by ongoing Phase 3 trials, such as salanersen for SMA, and upbeat annual profit forecasts, though shares remain below recent highs amid broader MS franchise pressures.
INCY Overview and Recent Performance
Incyte Corporation (INCY) focuses on oncology, hematology, and inflammation, with flagship products like Jakafi (ruxolitinib) for myelofibrosis and Opzelura cream for dermatological conditions. In recent weeks, INCY shares have experienced short-term pressure with a 3-7% monthly dip, yet boast a 39% one-year gain and 34% three-year rise. Q4 results highlighted 28% revenue growth to $1.51 billion, surpassing estimates, driven by Jakafi and Opzelura demand, though adjusted EPS of $1.80 missed consensus due to elevated expenses. Key developments include European approval for Zynyz (retifanlimab) in anal cancer and positive topline data for tafasitamab in lymphoma, enhancing pipeline visibility in high-growth areas like immunotherapy.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) is a global pharmaceutical powerhouse with a broad portfolio spanning vaccines, oncology, and rare diseases, including Prevnar, Eliquis, and Vyndaqel. Recent trading has shown resilience with YTD gains near 9% and modest one-year increases around 12%, though shares have dipped 1-2% in recent sessions amid sector rotation. Performance reflects post-COVID adjustments, with oncology trials like PADCEV plus Keytruda showing promise in bladder cancer and approvals for obesity drugs in China. Despite pipeline concerns and expected EPS declines, recent earnings beats and a focus on high-growth areas like inflammation sustain investor interest, with shares trading above key moving averages.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of the platform's top-performing AI trading bots, drawn from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots leverage AI for technical and fundamental analyses, delivering signals for stocks, ETFs, and crypto with impressive stats: annualized returns up to +216%, win rates of 60-95%, profit factors reaching 9+, and low drawdowns in volatile environments. Standouts include semiconductor-focused bots like SOXL at +103% annualized (71% win rate) and multi-ticker strategies in aerospace/energy exceeding +130% returns with profit factors over 2.5. Only the most suitable for current volatility—such as those exploiting sector rotations in biotech, semis, and infrastructure—earn trending status. Explore these high-conviction options to enhance your trading edge.
Head-to-Head Comparison
BIIB, INCY, and PFE contrast sharply in business models: BIIB's neurology focus offers high-growth potential via Alzheimer's and SMA therapies but faces MS erosion; INCY's targeted oncology/hematology emphasizes Jakafi dominance with emerging immuno-oncology; PFE provides diversified stability across vaccines and blockbusters like Eliquis. Recent momentum favors BIIB (30%+ yearly) over INCY (39% but recent dips) and PFE (modest gains). Risk factors include pipeline execution for all, with PFE most exposed to patent cliffs. Valuation sensitivity is lowest for PFE (attractive multiples), while sentiment tilts toward BIIB's catalysts and INCY's revenue trajectory in specialized sectors.
Tickeron AI Verdict
Tickeron’s AI currently favors BIIB due to superior trend consistency, recent outperformance versus peers and the sector, and multiple near-term catalysts from its neurology pipeline. While INCY shows revenue strength and PFE offers stability, BIIB's relative positioning suggests higher probability of continued upside in the prevailing biotech momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 1 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s), and PFE’s FA Score reflects 1 green FA rating(s).
- BIIB’s FA Score: 1 green, 4 red.
- INCY’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s), and PFE’s TA Score reflects 4 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 5 bearish.
- INCY’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +3.95% price change this week, while INCY (@Biotechnology) price change was +1.43% , and PFE (@Pharmaceuticals: Major) price fluctuated +0.66% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.06%. For the same industry, the average monthly price growth was +4.67%, and the average quarterly price growth was +7.76%.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +12.41%, and the average quarterly price growth was +11.94%.
Reported Earning Dates
BIIB is expected to report earnings on Apr 29, 2026.
INCY is expected to report earnings on Apr 28, 2026.
PFE is expected to report earnings on May 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+2.06% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+6.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | INCY | PFE | |
| Capitalization | 26.9B | 19.3B | 157B |
| EBITDA | 2.6B | 1.76B | 16.8B |
| Gain YTD | 4.176 | -1.873 | 12.373 |
| P/E Ratio | 20.86 | 15.12 | 20.24 |
| Revenue | 9.89B | 5.14B | 62.6B |
| Total Cash | 3.82B | 3.58B | 13.6B |
| Total Debt | 6.58B | 40.4M | 64B |
BIIB | INCY | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 69 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 69 Overvalued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 71 | 100 | |
SMR RATING 1..100 | 78 | 32 | 74 | |
PRICE GROWTH RATING 1..100 | 47 | 47 | 27 | |
P/E GROWTH RATING 1..100 | 13 | 100 | 37 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for INCY (69) in the Biotechnology industry, and is somewhat better than the same rating for BIIB (90) in the Biotechnology industry. This means that PFE's stock grew somewhat faster than INCY’s and somewhat faster than BIIB’s over the last 12 months.
INCY's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as PFE (100) in the Pharmaceuticals Major industry, and is in the same range as BIIB (100) in the Biotechnology industry. This means that INCY's stock grew similarly to PFE’s and similarly to BIIB’s over the last 12 months.
INCY's SMR Rating (32) in the Biotechnology industry is somewhat better than the same rating for PFE (74) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BIIB (78) in the Biotechnology industry. This means that INCY's stock grew somewhat faster than PFE’s and somewhat faster than BIIB’s over the last 12 months.
PFE's Price Growth Rating (27) in the Pharmaceuticals Major industry is in the same range as INCY (47) in the Biotechnology industry, and is in the same range as BIIB (47) in the Biotechnology industry. This means that PFE's stock grew similarly to INCY’s and similarly to BIIB’s over the last 12 months.
BIIB's P/E Growth Rating (13) in the Biotechnology industry is in the same range as PFE (37) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INCY (100) in the Biotechnology industry. This means that BIIB's stock grew similarly to PFE’s and significantly faster than INCY’s over the last 12 months.
| BIIB | INCY | PFE | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 69% | N/A |
| Stochastic ODDS (%) | 1 day ago 65% | 1 day ago 56% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 57% | 1 day ago 62% | 1 day ago 56% |
| MACD ODDS (%) | 1 day ago 55% | 1 day ago 64% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 58% | 1 day ago 63% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 60% | 1 day ago 51% |
| Advances ODDS (%) | 1 day ago 57% | 13 days ago 61% | 5 days ago 56% |
| Declines ODDS (%) | 12 days ago 72% | 6 days ago 60% | 12 days ago 57% |
| BollingerBands ODDS (%) | 1 day ago 48% | 1 day ago 64% | 1 day ago 58% |
| Aroon ODDS (%) | 1 day ago 64% | 1 day ago 59% | 1 day ago 53% |
Advertisement